Literature DB >> 2810503

Pattern of failure after radical retropubic prostatectomy for clinically and pathologically localized adenocarcinoma of the prostate: influence of tumor deoxyribonucleic acid ploidy.

M L Blute1, O Nativ, H Zincke, G M Farrow, T Therneau, M M Lieber.   

Abstract

From 1966 to 1980, 315 patients underwent bilateral pelvic lymphadenectomy and radical retropubic prostatectomy without adjuvant treatment for clinically and pathologically localized adenocarcinoma of the prostate. Followup was 5 to 21 years, with a median of 8 years. The disease was pathological stage A in 24 patients (8%) and pathological stage B in 291 (92%). A total of 45 patients (14.2%) experienced progression. Over-all, 28 patients (8.9%) suffered local recurrence at a mean of 6.6 years postoperatively (median 5.5 years). Local recurrence was noted as late as 15 years postoperatively. Over-all, systemic progression was observed in 25 patients (8%) after a mean of 4.7 years (median 6 years). Eight patients (2.5%) experienced local and systemic failure. The projected local and systemic failure rates at 15 years were 22% and 15%, respectively. Disease-specific survival at 15 years was 93%, since only 11 patients (3.4%) died of prostate cancer. In an age-matched case control analysis, after all prognostic variables were analyzed (Mayo grade, Gleason score, capsule involvement, number of foci, volume of tumor and deoxyribonucleic acid tumor ploidy), progression was related to nondiploid deoxyribonucleic acid tumor ploidy (p less than 0.0004) as determined by flow cytometry in 63% of the patients who evidenced progression versus 8% of the nonrecurrent group.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2810503     DOI: 10.1016/s0022-5347(17)39051-1

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  7 in total

Review 1.  Current and evolving uses of optical coherence tomography in the genitourinary tract.

Authors:  Mohit Gupta; Li-Ming Su
Journal:  Curr Urol Rep       Date:  2015-03       Impact factor: 3.092

2.  Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005.

Authors:  Danil V Makarov; Bruce J Trock; Elizabeth B Humphreys; Leslie A Mangold; Patrick C Walsh; Jonathan I Epstein; Alan W Partin
Journal:  Urology       Date:  2007-06       Impact factor: 2.649

3.  The natural history of men treated with deferred androgen deprivation therapy in whom metastatic prostate cancer developed following radical prostatectomy.

Authors:  Danil V Makarov; Elizabeth B Humphreys; Leslie A Mangold; Michael A Carducci; Alan W Partin; Mario A Eisenberger; Patrick C Walsh; Bruce J Trock
Journal:  J Urol       Date:  2007-11-14       Impact factor: 7.450

4.  Prognostic factors in prostate cancer.

Authors:  A Buhmeida; S Pyrhönen; M Laato; Y Collan
Journal:  Diagn Pathol       Date:  2006-04-03       Impact factor: 2.644

5.  Prostatic carcinoma: a multivariate analysis of prognostic factors.

Authors:  A Berner; S Harvei; S Tretli; S D Fosså; J M Nesland
Journal:  Br J Cancer       Date:  1994-05       Impact factor: 7.640

6.  Prediction of Pathological Stage in Patients with Prostate Cancer: A Neuro-Fuzzy Model.

Authors:  Georgina Cosma; Giovanni Acampora; David Brown; Robert C Rees; Masood Khan; A Graham Pockley
Journal:  PLoS One       Date:  2016-06-03       Impact factor: 3.240

7.  A Deep Belief Network and Dempster-Shafer-Based Multiclassifier for the Pathology Stage of Prostate Cancer.

Authors:  Jae Kwon Kim; Mun Joo Choi; Jong Sik Lee; Jun Hyuk Hong; Choung-Soo Kim; Seong Il Seo; Chang Wook Jeong; Seok-Soo Byun; Kyo Chul Koo; Byung Ha Chung; Yong Hyun Park; Ji Youl Lee; In Young Choi
Journal:  J Healthc Eng       Date:  2018-03-19       Impact factor: 2.682

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.